Shengsheng Yu1, Alex Z Fu2, Ying Qiu3, Samuel S Engel3, Ravi Shankar3, Kimberly G Brodovicz3, Swapnil Rajpathak3, Larry Radican3. 1. Merck Sharp & Dohme Co., 1 Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889. Electronic address: shengsheng.yu@merck.com. 2. Georgetown University Medical Center, 3300 Whitehaven Street NW, Suite 4100 - Milton Harris Bldg. Washington, DC 20007. Electronic address: zf54@georgetown.edu. 3. Merck Sharp & Dohme Co., 1 Merck Drive, P.O. Box 100, Whitehouse Station, NJ 08889.
Abstract
AIMS: Type 2 diabetes is a reported risk factor for more frequent and severe urinary tract infections (UTI). We sought to quantify the annual healthcare cost burden of UTI in type 2 diabetic patients. METHODS: Adult patients diagnosed with type 2 diabetes were identified in MarketScan administrative claims data. UTI occurrence and costs were assessed during a 1-year period. We examined UTI-related visit and antibiotic costs among patients diagnosed with UTI, comparing those with versus without a history of UTI in the previous year (prevalent vs. incident UTI cases). We estimated the total incremental cost of UTI by comparing all-cause healthcare costs in patients with versus without UTI, using propensity score-matched samples. RESULTS: Within the year, 8.2% (6,014/73,151) of subjects had ≥1 UTI, of whom 33.8% had a history of UTI. UTI-related costs among prevalent versus incident cases were, respectively, $603 versus $447 (p=0.033) for outpatient services, $1,607 versus $1,819 (p=NS) for hospitalizations, and $61 versus $35 (p<0.0001) for antibiotics. UTI was associated with a total all-cause incremental cost of $7,045 (95% CI: 4,130, 13,051) per patient with UTI per year. CONCLUSIONS: UTI is common and may impose a substantial direct medical cost burden among patients with type 2 diabetes.
AIMS: Type 2 diabetes is a reported risk factor for more frequent and severe urinary tract infections (UTI). We sought to quantify the annual healthcare cost burden of UTI in type 2 diabeticpatients. METHODS: Adult patients diagnosed with type 2 diabetes were identified in MarketScan administrative claims data. UTI occurrence and costs were assessed during a 1-year period. We examined UTI-related visit and antibiotic costs among patients diagnosed with UTI, comparing those with versus without a history of UTI in the previous year (prevalent vs. incident UTI cases). We estimated the total incremental cost of UTI by comparing all-cause healthcare costs in patients with versus without UTI, using propensity score-matched samples. RESULTS: Within the year, 8.2% (6,014/73,151) of subjects had ≥1 UTI, of whom 33.8% had a history of UTI. UTI-related costs among prevalent versus incident cases were, respectively, $603 versus $447 (p=0.033) for outpatient services, $1,607 versus $1,819 (p=NS) for hospitalizations, and $61 versus $35 (p<0.0001) for antibiotics. UTI was associated with a total all-cause incremental cost of $7,045 (95% CI: 4,130, 13,051) per patient with UTI per year. CONCLUSIONS:UTI is common and may impose a substantial direct medical cost burden among patients with type 2 diabetes.
Authors: Ana López-de-Andrés; Romana Albaladejo-Vicente; Domingo Palacios-Ceña; David Carabantes-Alarcon; José Javier Zamorano-Leon; Javier de Miguel-Diez; Marta Lopez-Herranz; Rodrigo Jiménez-García Journal: Int J Environ Res Public Health Date: 2020-12-16 Impact factor: 3.390